|| List of recent G Protein-related patents
|Pharmaceutical compositions comprising napthamides|
Disclosed herein are naphthamide and quinoline carboxamide compounds containing two bicyclic moieties, pharmaceutical compositions comprising those compounds and methods of using the compositions in the treatment of cancers mediated by cyclic-amp (camp) response element binding protein (creb). The disclosed compositions have utility in the treatment of lung, prostate and breast cancers in a human subject..
The present invention relates to novel bipyridyl derivatives of formula (i) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by atp consuming proteins like kinases plays a role, particularly to inhibitors of tgf-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.. .
|Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors|
This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of formula (i) wherein r1 is hydrogen, chloro, methyl or methoxy, r2 is hydrogen or methoxy, with the proviso that at least one of r1 and r2 is other than hydrogen, g1 represents chloro, (c1-c4)-alkyl, (c1-c4)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group —ch2—or3, —ch2—nr4r5 or —c(═o)—nr4r6, and g2 represents chloro, cyano, (c1-c4)-alkyl, or the group —cr8ar8b—oh, —ch2—nr2r10, —c(═o)—nr11r12 or —ch2—or15, having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.. .
|Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof|
Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin d derivative, such as 25-hydroxyvitamin d2 and/or 25-hydroxyvitamin d3, or a 25-hydroxyvitamin d analog, such as a vitamin d-c22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described.
|Expression vector and method for producing protein|
Provided are: an expression vector for secreting a protein (z) to be recovered or a fusion protein having the protein (z) moiety therein; a method for producing a transformant using the expression vector; the transformant; and a method for producing a protein using the transformant. An expression vector comprising an expression cassette containing a structural gene sequence (y) encoding a protein (y), a structural gene sequence (z) located downstream from the structural gene sequence (y) and encoding a protein (z) that is a protein to be recovered, and a promoter sequence and a terminator sequence for expressing a fusion protein containing the protein (y) moiety and the protein (z) moiety, characterized in that the protein (y) is a full-length protein of protein disulfide isomerase 1 (pdi1), a partial protein of pdi1, or a mutant protein of the full-length protein or the partial protein..
|Streptomyces strain that decomposes proteins recalcitrant to proteolysis|
The invention provides novel biologically pure cultures of microorganisms high in protease activity and capable of decomposing proteins recalcitrant to proteolysis as contained in garbage, waste water, organic waste liquids, industrial wastes and the like, a protease produced by such microorganisms and capable of decomposing proteins recalcitrant to proteolysis, and a method of utilizing the same. The novel culture is of a soil-derived microorganism belonging to streptomyces sp., or a strain derived therefrom, which produces a protease capable of efficiently decomposing proteins recalcitrant to proteolysis as contained in waste water, organic waste liquids, industrial wastes and so forth..
|Il-17 binding proteins|
Proteins that bind il-17 and/or il-17f are described along with there use in composition and methods for treating, preventing, and diagnosing il-17 related diseases and for detecting il-17 in cells, tissues, samples, and compositions.. .
|Genetically engineered herbicide resistant algae|
Algae transformed with one or more polynucleotides encoding proteins that confer herbicide resistance are provided. The algae can be grown in small or large scale cultures that include one or more herbicides for the production and isolation of various products..
|Method for detecting compound-binding protein|
A method for detecting the interactions of biomaterials by screening a prey that interacts with a bait includes preparing a cell which expresses a first construct including a translocation module, a first labeling material, and a first medium, and a third construct including a prey and a second labeling material; introducing a second construct into the prepared cell, the second construct including a bait and a second medium binding with the first medium; allowing the prey and the bait to interact each other; and confirming the interaction between the prey and the bait by detecting intracellular distributions of the first construct and the third construct.. .
|Method for detecting protein-protein interaction|
Determining an interaction between the first protein and the second protein according to the detection of the fluorescent focus.. .
|Method for designing rna binding protein utilizing ppr motif, and use thereof|
A method for designing a protein capable of binding in an rna base selective manner or rna base sequence specific manner is provided. The protein of the present invention is a protein containing one or more of ppr motifs (preferably 2 to 14 ppr motifs) each consisting of a polypeptide of 30- to 38-amino acid length represented by the formula 1 (wherein helix a is a moiety of 12-amino acid length capable of forming an α-helix structure, and is represented by the formula 2, wherein, in the formula 2, a1 to a12 independently represent an amino acid; x does not exist, or is a moiety of 1- to 9-amino acid length; helix b is a moiety of 11- to 13-amino acid length capable of forming an α-helix structure; and l is a moiety of 2- to 7-amino acid length represented by the formula 3, wherein, in the formula 3, the amino acids are numbered “i” (-1), “ii” (-2), and so on from the c-terminus side, provided that liii to lvii may not exist), and combination of three amino acids a1, a4 and lii, or combination of two amino acids a4, and lii is a combination corresponding to a target rna base or base sequence..
|In silico affinity maturation|
Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation.. .
|Combination therapy comprising an mmp-14 binding protein|
Proteins that bind to matrix metalloproteinase 14, combination therapies with such proteins and methods of using such proteins are described.. .
|Plasma kallikrein binding proteins|
Plasma kallikrein binding proteins and methods of using such proteins are described.. .
|Il-1 alpha dual variable domain immunoglobulins and uses thereof|
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
|Affinity chromatography matrix|
The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein z or the c domain of protein a or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins..
|Dimeric iap inhibitors|
Molecular mimics of smac are capable of modulating apoptosis through their interaction with cellular iaps (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the n-terminal tetrapeptide of iap-binding proteins, such as smac/diablo, hid, grim and reaper, which interact with a specific surface groove of iap.
|Tubulin-interacting protein, caltubin, promotes axonal growth|
A novel isolated protein, referred to herein as “caltubin”, is provided. Caltubin promotes axonal regeneration, and prevents or at least reduces axonal retraction in neurons..
|Fluorescent labeling of transfer rna and study of protein synthesis|
Provided are methods for labeling transfer rna comprising replacing the uracil component of a dihydrouridine of said transfer rna with a fluorophore. The disclosed methods may comprise fluorescent labeling of natural trnas (i.e., trnas that have been synthesized in a cell, for example, in a bacterium, a yeast cell, or a vertebrate cell) at dihydrouridine (d) positions, or fluorescent labeling of synthetic trnas.
|Methods of reducing or eliminating protein modification and degradation arising from exposure to uv light|
Methods of inactivation of a virus in a sample comprising a protein component are provided. Also provided are methods of reducing protein degradation or modification in to the presence of a reactive species, such as a reactive species generated as a result of uv exposure, are also provided.
|Lin28-mediated control of let-7 biogenesis|
The present embodiments provide for compositions and methods that regulate microrna-binding protein-mediated mirna biogensis; for example lin28-mediated biogenesis of let-7; and in particular lin28a-recruited 3′ terminal uridylyl transferase (tutase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit tutase-dependent lin28a-mediated repression of let-7 mirna..
|Apelin antigen-binding proteins and uses thereof|
This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis.
|Novel class of therapeutic protein based molecules|
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus.
|Fibrous protein processing method|
Disclosed is a process for preparing proteinaceous materials. The process comprises solubilising fibrous protein by contacting it with an alkaline solution, ageing the resulting mixture to form a homogenous solution, and coagulating the resulting solution to form the proteinaceous material.
|Blue-light inducible system for gene expression|
The present invention provides methods for light-dependent gene regulation using a light-responsive dna-binding protein. Also provided are related nucleic acid molecules, and protein molecules, such as those encoding or comprising the light-responsive dna-binding protein or dna-binding sites recognizing the light-responsive dna-binding protein.
A streamlined method for purifying alpha-1-antitrypsin (aat) from an aat-containing protein mixture, such as a cohn fraction iv precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect aat.
|Method for increasing protein thermal stability|
The invention provides a simple and effective method for increasing thermal stability of a wide range of proteins, comprising fusing a self-assembling amphipathic peptide to the c- or n-terminal of target proteins. The fusion protein can have a half life up to 26 times longer than that of the wild type protein..
|Chemically modified sophorolipids and uses thereof|
The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture.
|Refolding transforming growth factor beta family proteins|
Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product..
|Restructured natural protein matrices|
Methods as can be used in the preparation of one or more dairy, dairy analog and cheese products from a range of proteinacous starting materials, such methods comprising protein modification and protein restoration or protein restructure.. .
|Specific binding proteins and uses thereof|
The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to egfr on tumor cells that overexpress egfr, and on tumor cells that express the truncated version of the egfr receptor, de2-7 egf. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification.
Provided are methods for reducing levels of cyanogenic glycosides and improving protein content in plants, as well as plants containing reduced levels of cyanogenic glycosides and improved protein content. In one aspect, such methods comprise, and such plants are created via, tissue-specific expression of a storage protein such as hydroxynitrile lyase in the apoplastic space of cells of the roots and tubers of such plants..
|Polymers and plastics derived from animal proteins|
The invention is directed to a method for preparing a polymer derived from an animal protein, such as in a feedstock derived from animal by-products. The method involves hydrolyzing proteins present in a feedstock to obtain hydrolyzed proteins, wherein hydrolysis is conducted under conditions sufficient to digest the proteins and destroy pathogens; extracting a protein fraction from the hydrolyzed proteins; and treating the protein fraction with a crosslinking reagent to form the polymer.
|Binding inhibitors of the beta. transducin repeat-containing protein|
The present invention relates to compounds which bind to beta trans-ducin repeat-containing protein (ptrcp), and modulate the activity of 13trcp. In particular, the invention relates to compounds which demonstrate optimised binding to ptrcp.
The present invention relates to reagents for separating proteins from detergent, reagents for detecting proteins in the presence of a detergent, and methods of using the same. The separating reagents contain a cyclic oligomer such as cyclodextrin and a cellulose derivative such as 2-hydroxyethyl cellulose.
|Chaperone interaction assays and uses thereof|
In some aspects, the invention provides methods of identifying, detecting, and/or measuring protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein-protein interactions.
|Method for extracting protein from kaniwa and protein products thereof|
Provided herein is a method for making a protein product from kaniwa. The method comprises milling the kaniwa.
|Whipping agent for food products and use thereof|
The present invention relates to a whipping agent comprising protein and emulsifier for aerated food products, such as for sorbet and sherbet applications. The present invention also relates to whipped food products such as sorbets and sherbets comprising this whipping agent and a method for making the same.
|Proteomics based diagnostic detection method for chronic sinusitis|
The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria.
|Methods of treating epidermal growth factor deletion mutant viii related disorders|
The present invention relates to methods of treating treating epidermal growth factor deletion mutant viii (egfrviii) related disorders, such as glioblastoma or anaplastic astrocyte tumors, using antigen binding proteins, including antibodies against egfrviii conjugated to a drug. Diagnostic and therapeutic formulations of such antibodies and drug conjugates thereof are also provided..
|System and method for multiplexed biomarker quantitation using single cell segmentation on sequentially stained tissue|
Improved systems and methods for the analysis of digital images are provided. More particularly, the present disclosure provides for improved systems and methods for the analysis of digital images of biological tissue samples.
|Native protein electrophoresis and methods of use|
A method of characterizing proteins has been developed that includes providing a sample that contains a plurality of proteins to be characterized, wherein at least a first protein of the plurality of proteins is in its native form. Additionally, the method includes contacting the sample containing the plurality of proteins with a solution to form a sample solution, and then contacting the sample solution with a gel.
|Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto|
That are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion..
|Inhibiting g protein coupled receptor 6 kinase polypeptides|
This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
|Compositions and methods for immunomodulation|
The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the c4b-binding protein (c4bp) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease.
|Remedy for diabetes|
A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the β subunit of a trimeric gtp-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the β subunit of a trimeric gtp-binding protein, as the active ingredient, etc..
|Hydrogenase polypeptide and methods of use|
Provided herein are polypeptides having hydrogenase activity. The polypeptide may be multimeric, and may have hydrogenase activity of at least 0.05 micromoles h2 produced min−1 mg protein−1.
|Protein fortified yogurts and methods of making|
Methods of making protein-fortified yogurt products are described. The methods may include mixing a casein-containing ingredient with starting milk to make a yogurt milk, where the casein-containing ingredient has a casein-to-whey protein ratio of 82:18 or greater.
|Meal intended for human consumption|
This invention relates to a plurality of compositions for dietary health management and its use in the prevention or treatment of cardiovascular disease or type 2 diabetes, and also in the prevention and/or management of obesity and generally in weight management and loss. Thus a meal intended for human consumption is provided, the meal comprising: (a) 250-650 kilocalories (1045-4180 kilojoules); (b) 10-50, preferably 20-50, more preferably 30-50 g fibre; (c) 10-50, preferably 10-30, more preferably 10-20 g protein; (d) 0 to 5, preferably less than 3 g starch; and (e) 0 to 2, preferably 0 to 1, most preferably 0 to 0.5 g lactose; (f) at least 20, preferably at least 30, most preferably at least 40 mg of any one flavonoid aglycone; and (g) at least 30, preferably at least 40, most preferably at least 50 mg of any one flavonoid glucoside; wherein the meal comprises 75-1000 mg of total flavonoid aglycone and flavonoid glucoside, wherein the meal comprises no more than 250 mg of any one flavonoid aglycone, wherein the meal comprises no more than 250 mg of any one flavonoid glucoside..
Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to erbb3 and aspects relating to such constructs..
|Dual variable domain immunoglobulins and uses thereof|
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
|Vectors conditionally expressing protein|
This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals.
|Fc receptor binding proteins|
The disclosure relates to antibodies that bind fcrn and methods of using these antibodies.. .